METHOD OF TREATING PROSTATE CANCER USING A COMBINATION BASED ON ANDROGEN RECEPTOR MODULATOR

The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a...

Full description

Saved in:
Bibliographic Details
Main Authors HERBERT, Mark R, SMITH, Nicholas D, HAGER, Jeffrey H, CHEN, Isan, MANEVAL, Edna Chow
Format Patent
LanguageEnglish
Russian
Published 29.04.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient comprising orally administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the male human patient in need of such treatment at a dose of 30 to 480 mg per day in combination with (a) abiraterone acetate and (b) prednisone. Изобретение относится к способу лечения метастатического кастрационно-резистентного рака предстательной железы, неметастатического кастрационно-резистентного рака предстательной железы, метастатического кастрационно-чувствительного рака предстательной железы, неметастатического кастрационно-чувствительного рака предстательной железы или локализованного рака предстательной железы высокого риска у пациента-человека мужского пола, включающему пероральное введение соединения формулы (I) или его фармацевтически приемлемой соли пациенту-человеку мужского пола, нуждающемуся в таком лечении, в дозе от 30 до 480 мг в сутки в комбинации с (a) абиратерон ацетатом и (b) преднизоном.
AbstractList The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient comprising orally administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the male human patient in need of such treatment at a dose of 30 to 480 mg per day in combination with (a) abiraterone acetate and (b) prednisone. Изобретение относится к способу лечения метастатического кастрационно-резистентного рака предстательной железы, неметастатического кастрационно-резистентного рака предстательной железы, метастатического кастрационно-чувствительного рака предстательной железы, неметастатического кастрационно-чувствительного рака предстательной железы или локализованного рака предстательной железы высокого риска у пациента-человека мужского пола, включающему пероральное введение соединения формулы (I) или его фармацевтически приемлемой соли пациенту-человеку мужского пола, нуждающемуся в таком лечении, в дозе от 30 до 480 мг в сутки в комбинации с (a) абиратерон ацетатом и (b) преднизоном.
Author HERBERT, Mark R
SMITH, Nicholas D
CHEN, Isan
MANEVAL, Edna Chow
HAGER, Jeffrey H
Author_xml – fullname: HERBERT, Mark R
– fullname: SMITH, Nicholas D
– fullname: HAGER, Jeffrey H
– fullname: CHEN, Isan
– fullname: MANEVAL, Edna Chow
BookMark eNqFi0sKg0AQBWeRLPI7Q_oCgRjxAO3YfiB2y9iuXIiEySqMgrk_MZB9Vq8o6u3NJkzB70xfk5aSgeSgjlArLqBx0ioqgUW25KBrvxbBSp1WvDbCkGJL64sBOXNSEIMjS42Kg1qy7o4rHc32Ob4Wf_rtwZxzUlte_DwNfpnHhw_-PRBe4yS6JWkU_y8-5qcyuw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate СПОСОБ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ НА ОСНОВЕ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА
ExternalDocumentID EA035125B1
GroupedDBID EVB
ID FETCH-epo_espacenet_EA035125B13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:19:49 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Russian
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EA035125B13
Notes Application Number: EA20150091340
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200429&DB=EPODOC&CC=EA&NR=035125B1
ParticipantIDs epo_espacenet_EA035125B1
PublicationCentury 2000
PublicationDate 20200429
PublicationDateYYYYMMDD 2020-04-29
PublicationDate_xml – month: 04
  year: 2020
  text: 20200429
  day: 29
PublicationDecade 2020
PublicationYear 2020
RelatedCompanies ARAGON PHARMACEUTICALS, INC
RelatedCompanies_xml – name: ARAGON PHARMACEUTICALS, INC
Score 3.2546408
Snippet The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer,...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title METHOD OF TREATING PROSTATE CANCER USING A COMBINATION BASED ON ANDROGEN RECEPTOR MODULATOR
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200429&DB=EPODOC&locale=&CC=EA&NR=035125B1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NT8IwFG8IGvWmqMHvHsxui2y0kB0W07UdYNy6jGJIPBC2QvQyCIz479tOUC_cmjZ9aV_yvvr6fg-ARzTFqOMoz3bnGbKR185sT7WUjXKlve1uF09bpnY4ijv9EXoZ43ENfOxqYSqc0K8KHFFLVK7lvaz09fLvEYtVfyvXT9mnnlo8h9Jn1jY6div9arHA54lgglqU-pxYceqbhJmLAx0nHRgn2qDs87fA1KQs_xuU8BQcJppWUZ6B2mrTAMd013etAY6ibbpbD7eStz4H7xGXfcGgCKFMOZGDuAeTVAwlkRxS02EmhaaFRg8SSEUUDH5gbmFAhlzviiGJWSp6PIYppzyRIoWRYKNXokcX4CHkkvZtfcrJL0MmnOyu074E9WJRzJoAdpCT47nS7ojjIcdTmQ7s8kzhfO7g3FHTK9DcR-V6_9INODFsNfkT17sF9XK1md1pM1xm9xUHvwEdG4TM
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NT8IwFG8IGvGmqMFPejC7LbLRQXZYTNd2DGXrMooh8UDYCtELEBjx37edoF64NW360r7kffX1_R4Aj2jqoI4lXdOeZ8hEbjszXdmSJsql8ra7XWfa0rXDUdwJR-hl7Iwr4GNfC1PihH6V4IhKonIl70Wpr1d_j1i0_Fu5eco-1dTyORAeNXbRsV3qV4P6Hks45cQgxGPYiFNPJ8xsx1dx0lFXY_Nqx-nN1zUpq_8GJTgDx4mitSjOQWW9rYMa2fddq4OTaJfuVsOd5G0uwHvERMgp5AEUKcOiH_dgkvKhwIJBojvMpFC30OhBDAmP_P4PzC308ZCpXTHEMU15j8UwZYQlgqcw4nQ0wGp0CZoBEyQ01SknvwyZMLy_TvsKVBfLxawBYAdZuTOXyh2xXGS5MlOBXZ5JJ59bTm7J6TVoHKJyc3ipCWqhiAaTQT9-vQWnmsU6l2K7d6BarLeze2WSi-yh5OY3e7yHuQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=METHOD+OF+TREATING+PROSTATE+CANCER+USING+A+COMBINATION+BASED+ON+ANDROGEN+RECEPTOR+MODULATOR&rft.inventor=HERBERT%2C+Mark+R&rft.inventor=SMITH%2C+Nicholas+D&rft.inventor=HAGER%2C+Jeffrey+H&rft.inventor=CHEN%2C+Isan&rft.inventor=MANEVAL%2C+Edna+Chow&rft.date=2020-04-29&rft.externalDBID=B1&rft.externalDocID=EA035125B1